How Will Ozempic and Wegovy Sales Aid NVO’s Upcoming Q3 Results?
Novo Nordisk NVO is a dominant player in the cardiometabolic space, mainly due to the encouraging uptake of its…
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug…
Wegovy® approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis
“Today’s decision by the FDA reflects the continued progress in how we understand and treat patients with MASH,…